Compare ELTX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | ARCT |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 189.9M |
| IPO Year | 2014 | 2019 |
| Metric | ELTX | ARCT |
|---|---|---|
| Price | $12.50 | $8.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $18.00 | ★ $24.11 |
| AVG Volume (30 Days) | 110.2K | ★ 469.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $5.85 |
| 52 Week High | $14.93 | $24.14 |
| Indicator | ELTX | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 69.76 |
| Support Level | $9.85 | $6.08 |
| Resistance Level | $12.52 | $15.20 |
| Average True Range (ATR) | 0.95 | 0.45 |
| MACD | 0.26 | 0.10 |
| Stochastic Oscillator | 64.98 | 89.00 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.